CSTL
Castle Biosciences Inc (CSTL)
Healthcare • NASDAQ • $19.83+3.07%
- Symbol
- CSTL
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Price
- $19.83
- Daily Change
- +3.07%
- Market Cap
- $601.44M
- Trailing P/E
- N/A
- Forward P/E
- -24.56
- 52W High
- $44.28
- 52W Low
- $14.59
- Analyst Target
- $47.25
- Dividend Yield
- N/A
- Beta
- 1.11
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with mode…
Company websiteResearch CSTL on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.